FDA says rapid antigen COVID-19 tests may be less accurate against omicron

Published



The Food and Drug Administration said it believes rapid antigen tests may be more likely to produce false negatives against omicron than other variants of COVID-19.

The FDA authorizes the use of antigen tests to identify COVID-19 but recommends individuals with symptoms take a molecular test.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.